Evaluation of the Efficacy and Safety of Diacerein in Patients With Osteoarthritis of the Hip Joints

Шарапова, Е. П.; Кашеварова, Н. Г.; Зайцева, Е. М.; Аникин, С. Г.; Короткова, Т. А.; Алексеева, Л. И.

doi:10.21518/2079-701x-2017-0-84-89

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Шараповой и соавт. [70], в котором изучалась эффек-тивность Д 2 у больных ОА тазобедренного сустава. 30 боль-ных в течение 4 мес получали Д 100 мг/сут, при этом резуль-таты лечения оценивались в ходе всего периода активной терапии и через 2 мес после ее прекращения.…”

Section: ф а к т о р ы в л и я ю щ и е н а н е д о с т а т о ч н о unclassified

Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution

Каратеев¹

2017

RJTAO

View full text Add to dashboard Cite

Идеальная стратегия терапии любого заболевания предполагает этиотропный и патогенетический подход. Всегда следует искать причину болезни (например, если ее развитие вызвано инфекционным агентом), а когда это не-возможно (как в подавляющем большинстве случаев при хронических заболеваниях), четко выделить основные зве-нья ее патогенеза. Точное знание направления фармакоте-рапии ориентирует на очень высокий результат, которого можно достичь в процессе лечения: полное прекращение прогрессирования болезни, т. е. стойкая медикаментозная, а при благоприятном стечении обстоятельств и безмедика-ментозная ремиссия или даже полное выздоровление. (non-steroidal anti-inflammatory drugs (NSAIDs), opioids, local glucocorticoid injections, duloxetine, etc.) Effective control of musculoskeletal pain (MSP) is one of the main tasks of medical care for the most common rheumatic diseases, such as osteoarthritis (OA) and non-specific back pain (NSBP). Epidemiological surveys have shown that a substantial proportion (about 40-50%) of patients consider their assigned treatment to be ineffective and are dissatisfied with its results. The reasons for this are a phenotypic diversity of MSP, individual responses to analgesic drugs, and comorbidities (particularly metabolic disorders and depression). Placebo-controlled trials have demonstrated that monotherapy with the most popular drugs

show abstract

Section: ф а к т о р ы в л и я ю щ и е н а н е д о с т а т о ч н о unclassified

Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution

Каратеев¹

2017

RJTAO

View full text Add to dashboard Cite

show abstract

Diacerein in the treatment of osteoarthritis in patients with comorbidity

Шарапова¹,

Алексеева²,

Лила³

2018

Sovremennaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Osteoarthritis (OA) belongs to diseases with high comorbidity and is most frequently concurrent with hypertension and other cardiovascular diseases (coronary heart disease, atherosclerosis), obesity, and diabetes mellitus. The paper deals with the use of delayed-release symptomatic medications in the treatment of patients with OA and comorbidity. It reviews clinical trials of the efficacy and safety of diacerein in OA patients and its effect on comorbidity. The paper discusses the possibility of using diacerein as an alternative to traditional nonsteroidal anti-inflammatory drugs in patients with contraindications to the latter.

show abstract

Diacerein in the treatment of chronic musculoskeletal pain

Polishchuk¹,

Karateev²

2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Chronic musculoskeletal pain (MSP) is the most painful manifestation of rheumatic diseases (RD), the main cause of disability, a decrease in the quality and life expectancy of patients, which determines not only the high medical, but also the social significance of this problem. The chronic nature of the pain forces patients with MSP to use analgesic therapy for a long time. At the same time, non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for MSP. However, it is well known that the use of this group of drugs is associated with significant difficulties, mainly due to the comorbid pathology that is common in middle-aged and elderly people. In this regard, there are continuing attempts at searching for alternative agents for chronic MSP control, which have analgesic and anti-inflammatory activity similar to NSAIDs, but lack their side effects. Some researchers believe that diacerein can become such drug.

show abstract

Evaluation of the Efficacy and Safety of Diacerein in Patients With Osteoarthritis of the Hip Joints

Cited by 4 publications

References 9 publications

Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution

Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution

Diacerein in the treatment of osteoarthritis in patients with comorbidity

Diacerein in the treatment of chronic musculoskeletal pain

Contact Info

Product

Resources

About